keyword
MENU ▼
Read by QxMD icon Read
search

Lisdexamfetamine

keyword
https://www.readbyqxmd.com/read/28651185/treatment-of-neurocognitive-symptoms-in-unipolar-depression-a-systematic-review-and-future-perspectives
#1
REVIEW
E Salagre, B Solé, Y Tomioka, B S Fernandes, D Hidalgo-Mazzei, M Garriga, E Jimenez, J Sanchez-Moreno, E Vieta, I Grande
BACKGROUND: Cognitive symptoms in Major Depressive Disorder (MDD) are persistent and commonly entail neurocognitive impairment and a decline in quality of life. This systematic review gathers the current scientific evidence on therapeutic strategies for neuropsychological impairment in MDD. METHOD: A systematic search on PubMed, PsycINFO and Clinicaltrials.gov was carried out on December 2016 according to PRISMA using Boolean terms to identify interventions for the treatment of cognitive dysfunction in MDD...
June 19, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28590365/the-efficacy-of-psychostimulants-in-major-depressive-episodes-a-systematic-review-and-meta-analysis
#2
Roger S McIntyre, Yena Lee, Aileen J Zhou, Joshua D Rosenblat, Evyn M Peters, Raymond W Lam, Sidney H Kennedy, Carola Rong, Jeanette M Jerrell
BACKGROUND: Psychostimulants are frequently prescribed off-label for adults with major depressive disorder or bipolar disorder. The frequent and increasing usage of stimulants in mood disorders warrants a careful appraisal of the efficacy of this class of agents. Herein, we aim to estimate the efficacy of psychostimulants in adults with unipolar or bipolar depression. METHODS: The PubMed/Medline database was searched from inception to January 16, 2016 for randomized, placebo-controlled clinical trials investigating the antidepressant efficacy of psychostimulants in the treatment of adults with unipolar or bipolar depression...
August 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28547702/emerging-treatments-in-eating-disorders
#3
REVIEW
Michael Lutter
Eating disorders (EDs), including anorexia nervosa, bulimia nervosa, and binge-eating disorder, constitute a class of common and deadly psychiatric disorders. While numerous studies in humans highlight the important role of neurobiological alterations in the development of ED-related behaviors, the precise neural substrate that mediates this risk is unknown. Historically, pharmacological interventions have played a limited role in the treatment of eating disorders, typically providing symptomatic relief of comorbid psychiatric issues, like depression and anxiety, in support of the standard nutritional and psychological treatments...
May 25, 2017: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://www.readbyqxmd.com/read/28513760/cell-therapy-in-the-treatment-of-bipolar-mania-in-an-animal-model-a-proof-of-concept-study
#4
Bruna M Ascoli, Rafael Colombo, Luiza P Géa, Paula B Terraciano, Sabrina B Pizzato, Fernanda S de Oliveira, Elizabeth Cirne-Lima, Flávio Kapczinski, Adriane R Rosa
Introduction: The rationale of mesenchymal stem cells (MSCs) as a novel therapeutic approach in certain neurodegenerative diseases is based on their ability to promote neurogenesis. Hippocampal atrophy has been related to bipolar disorder (BD) in preclinical, imaging and postmortem studies. Therefore, the development of new strategies to stimulate the neurogenesis process in BD is crucial. Objectives: To investigate the behavioral and neurochemical changes induced by transplantation of MSCs in a model of mania-like behavior induced by lisdexamfetamine dimesylate (LDX)...
May 15, 2017: Trends in Psychiatry and Psychotherapy
https://www.readbyqxmd.com/read/28481434/time-course-of-the-effects-of-lisdexamfetamine-dimesylate-in-two-phase-3-randomized-double-blind-placebo-controlled-trials-in-adults-with-binge-eating-disorder
#5
Susan L McElroy, James I Hudson, Maria Gasior, Barry K Herman, Jana Radewonuk, Denise Wilfley, Joan Busner
OBJECTIVE: This study examined the time course of efficacy-related endpoints for lisdexamfetamine dimesylate (LDX) versus placebo in adults with protocol-defined moderate to severe binge eating disorder (BED). METHODS: In two 12-week, double-blind, placebo-controlled studies, adults meeting DSM-IV-TR BED criteria were randomized 1:1 to receive placebo or dose-optimized LDX (50 or 70 mg). Analyses across visits used mixed-effects models for repeated measures (binge eating days/week, binge eating episodes/week, Yale-Brown Obsessive Compulsive Scale modified for Binge Eating [Y-BOCS-BE] scores, percentage body weight change) and chi-square tests (Clinical Global Impressions-Improvement [CGI-I; from the perspective of BED symptoms] scale dichotomized as improved or not improved)...
May 8, 2017: International Journal of Eating Disorders
https://www.readbyqxmd.com/read/28467032/comparative-effectiveness-of-treatments-for-binge-eating-disorder-systematic-review-and-network-meta-analysis
#6
REVIEW
Christine M Peat, Nancy D Berkman, Kathleen N Lohr, Kimberly A Brownley, Carla M Bann, Katherine Cullen, Mary J Quattlebaum, Cynthia M Bulik
Psychological and pharmacological interventions for binge-eating disorder have previously demonstrated efficacy (compared with placebo or waitlist control); thus, we aimed to expand that literature with a review of comparative effectiveness. We searched MEDLINE,® EMBASE,® Cochrane Library, Academic OneFile, CINAHL® for binge-eating disorder treatment articles and selected studies using predetermined inclusion and exclusion criteria. Data were sufficient for network meta-analysis comparing two pharmacological interventions; psychological interventions were analysed qualitatively...
May 3, 2017: European Eating Disorders Review: the Journal of the Eating Disorders Association
https://www.readbyqxmd.com/read/28440070/chiral-analysis-of-amphetamines-in-hair-by-liquid-chromatography-tandem-mass-spectrometry-compliance-monitoring-of-attention-deficit-hyperactivity-disorder-adhd-patients-under-elvanse%C3%A2-therapy-and-identification-after-controlled-low-dose-application
#7
Tina M Binz, Elena Williner, Petra Strajhar, Patrick C Dolder, Matthias E Liechti, Markus R Baumgartner, Thomas Kraemer, Andrea E Steuer
Amphetamine (AMP) is used as illicit drug but also for the treatment of attention deficit hyperactivity disorder (ADHD). Respective drugs most often contain the enantiomer (S)-AMP as active compound or (S)-AMP is formed from the prodrug lisdexamfetamine (Elvanse®) whereas the illicit drug is usually traded as racemate ((R/S)-AMP). A differentiation between the use of the medically prescribed drug and the abuse of illicit street amphetamine is of great importance e.g. in retrospective consumption monitoring by hair analysis...
April 24, 2017: Drug Testing and Analysis
https://www.readbyqxmd.com/read/28383364/a-phase-3-multicenter-open-label-12-month-extension-safety-and-tolerability-trial-of-lisdexamfetamine-dimesylate-in-adults-with-binge-eating-disorder
#8
Maria Gasior, James Hudson, Javier Quintero, M Celeste Ferreira-Cornwell, Jana Radewonuk, Susan L McElroy
BACKGROUND: A 12-month, open-label extension study assessed the long-term safety and tolerability of lisdexamfetamine dimesylate (LDX) in adults with binge eating disorder (BED). METHODS: Adults (aged 18-55 y) with BED who completed 1 of 3 antecedent studies were enrolled in a 52-week, open-label extension study (dose optimization, 4 weeks [initial titration dose, 30-mg LDX; target doses, 50- or 70-mg LDX]; dose maintenance, 48 weeks). Safety evaluations included the occurrence of treatment-emergent adverse events (TEAEs), vital sign and weight assessments, and Columbia-Suicide Severity Rating Scale responses...
June 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28376679/dopamine-and-%C3%AE-opioid-receptor-dysregulation-in-the-brains-of-binge-eating-female-rats-possible-relevance-in-the-psychopathology-and-treatment-of-binge-eating-disorder
#9
David J Heal, Michelle Hallam, Michael Prow, Jane Gosden, Sharon Cheetham, Yong K Choi, Frank Tarazi, Peter Hutson
Adult, female rats given irregular, limited access to chocolate develop binge-eating behaviour with normal bodyweight and compulsive/perseverative and impulsive behaviours similar to those in binge-eating disorder. We investigated whether (a) dysregulated central nervous system dopaminergic and opioidergic systems are part of the psychopathology of binge-eating and (b) these neurotransmitter systems may mediate the actions of drugs ameliorating binge-eating disorder psychopathology. Binge-eating produced a 39% reduction of striatal D1 receptors with 22% and 23% reductions in medial and lateral caudate putamen and a 22% increase of striatal μ-opioid receptors...
June 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28372478/investigation-of-impulsivity-in-binge-eating-rats-in-a-delay-discounting-task-and-its-prevention-by-the-d-amphetamine-prodrug-lisdexamfetamine
#10
Steven P Vickers, Simon Goddard, Richard J Brammer, Peter H Hutson, David J Heal
Freely-fed, female, rats were trained in a two-lever, delay-discounting task: one lever delivered a single chocolate-flavoured pellet immediately and the other a three-pellet reward after increasing delay (0, 4, 8, 16, 32 s). Rats were divided into two groups (i.e. binge-eating rats given irregular, limited access to chocolate in addition to normal chow and controls maintained on normal chow). Both groups exhibited increased preference for the immediate reward as the delay interval was lengthened. The discounting rate was significantly greater in binge-eating rats than non-binge-eating controls, especially as the behaviour became more established indicating that increased impulsivity and intolerance of delayed reward are part of the psychopathology of binge-eating...
June 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28351466/adhd-in-germany-trends-in-diagnosis-and-pharmacotherapy
#11
Christian J Bachmann, Alexandra Philipsen, Falk Hoffmann
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) sometimes persists into adulthood. There have been no studies from Germany until the present time on the diagnosis and treatment of ADHD over the course of patients' lives, in particular during the transition from adolescence to early adulthood. METHODS: We used nationwide routine data of the AOK statutory healthinsurance fund to determine the frequency of ADHD diagnoses and prescriptions of medication for ADHD...
March 3, 2017: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/28334528/why-prodrugs-and-propesticides-succeed
#12
REVIEW
John E Casida
What are the advantages of bioactivation in optimizing drugs and pesticides? Why are there so many prodrugs and propesticides? These questions are examined here by considering compounds selected on the basis of economic value or market success in 2015. The 100 major drugs and 90 major pesticides are divided into ones acting directly and those definitely or possibly requiring bioactivation. Established or candidate prodrugs accounted for 19% of the total drug sales, with corresponding values of 20, 37, and 17% for proinsecticides, proherbicides, and profungicides...
May 15, 2017: Chemical Research in Toxicology
https://www.readbyqxmd.com/read/28258319/comparative-efficacy-and-safety-of-attention-deficit-hyperactivity-disorder-pharmacotherapies-including-guanfacine-extended-release-a-mixed-treatment-comparison
#13
REVIEW
Alain Joseph, Rajeev Ayyagari, Meng Xie, Sean Cai, Jipan Xie, Michael Huss, Vanja Sikirica
This study compared the clinical efficacy and safety of attention-deficit/hyperactivity disorder (ADHD) pharmacotherapy in children and adolescents 6-17 years of age. A systematic literature review was conducted to identify randomized controlled trials (RCTs) of pharmacologic monotherapies among children and adolescents with ADHD. A Bayesian network meta-analysis was conducted to compare change in symptoms using the ADHD Rating Scale Version IV (ADHD-RS-IV), Clinical Global Impression-Improvement (CGI-I) response, all-cause discontinuation, and adverse event-related discontinuation...
March 3, 2017: European Child & Adolescent Psychiatry
https://www.readbyqxmd.com/read/28246413/dexmedetomidine-to-control-signs-associated-with-lisdexamfetamine-dimesylate-toxidrome-in-a-cat
#14
Christopher L Norkus, Iain Keir, Charlotte Means
A 5-month-old intact female domestic shorthaired cat had mydriasis, agitation, and increased locomotion after ingestion of lisdexamfetamine, 10.3 mg/kg body weight (BW). Despite treatment with IV fluids, IV acepromazine, oral cyproheptadine and intravenous lipid emulsion the patient's clinical signs worsened. Dexmedetomidine administered at 2 μg/kg BW and continued at 0.5 μg/kg BW per hour rapidly controlled the patient's signs. An episode of vomiting and hematuria developed. Follow-up 5 days after discharge revealed that the cat appeared normal...
March 2017: Canadian Veterinary Journal. la Revue Vétérinaire Canadienne
https://www.readbyqxmd.com/read/28125174/pharmacologic-treatments-for-binge-eating-disorder
#15
REVIEW
Susan L McElroy
Binge-eating disorder (BED) is the most common eating disorder and is associated with poor physical and mental health outcomes. Psychological and behavioral interventions have been a mainstay of treatment for BED, but as understanding of this disorder has grown, pharmacologic agents have become promising treatment options for some patients. At this time, only one drug-the stimulant prodrug lisdexamfetamine-is approved for the treatment of BED. Numerous classes of medications including antidepressants, anticonvulsants, and antiobesity drugs have been explored as off-label treatments for BED with variable success...
2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28114089/-non-conventional-pharmacological-agents-for-the-treatment-of-bipolar-disorder-%C3%AE-systematic-review-of-the-evidence
#16
REVIEW
K N Fountoulakis, D Balaris, V Nikolaou, J Νimatoudis
Bipolar disorder (BD) has a complex and variable clinical picture which is characterized by many different phacets and phases and as a result its therapeutical options are also complex and often unsatisfactory. Typically the so-called "mood stabilizers" are used in the treatment of BD and in this class lithium and specific antiepileptics are included. The present study aimed to systematically review the literature concerning the presence of randomized double blind clinical trials of 'non conventional' pharmaceutical treatment options...
October 2016: Psychiatrikē, Psychiatriki
https://www.readbyqxmd.com/read/28093662/a-cost-effectiveness-analysis-of-lisdexamfetamine-dimesylate-in-the-treatment-of-adults-with-attention-deficit-hyperactivity-disorder-in-the-uk
#17
Evelina A Zimovetz, Alain Joseph, Rajeev Ayyagari, Josephine A Mauskopf
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurobehavioral disorder in children that may persist into adulthood. Lisdexamfetamine dimesylate (LDX) is approved in many countries for ADHD treatment in children, adolescents, and adults. OBJECTIVES: Estimate the cost-effectiveness of LDX as a first- or second-line treatment for adults with ADHD from the United Kingdom (UK) National Health Service (NHS) perspective compared with methylphenidate extended release (MPH-ER) and atomoxetine (ATX)...
January 16, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28073796/comparative-efficacy-and-tolerability-of-pharmacological-interventions-for-attention-deficit-hyperactivity-disorder-in-children-adolescents-and-adults-protocol-for-a-systematic-review-and-network-meta-analysis
#18
Samuele Cortese, Nicoletta Adamo, Christina Mohr-Jensen, Adrian J Hayes, Sahar Bhatti, Sara Carucci, Cinzia Del Giovane, Lauren Z Atkinson, Tobias Banaschewski, Emily Simonoff, Alessandro Zuddas, Corrado Barbui, Marianna Purgato, Hans-Christoph Steinhausen, Farhad Shokraneh, Jun Xia, Andrea Cipriani, David Coghill
INTRODUCTION: Attention-deficit/hyperactivity disorder (ADHD) is a major public health issue. Pharmacological treatments play an important role in the multimodal treatment of ADHD. Currently, there is a lack of up-to-date and comprehensive evidence on how available ADHD drugs compare and rank in terms of efficacy and tolerability, in children or adolescents as well as in adults. We will conduct a network meta-analysis (NMA), integrating direct and indirect comparisons from randomised controlled trials (RCTs), to rank pharmacological treatments for ADHD according to their efficacy and tolerability profiles...
January 10, 2017: BMJ Open
https://www.readbyqxmd.com/read/27993933/pharmacological-and-non-pharmacological-treatment-of-adults-with-adhd-a-meta-review
#19
Franco De Crescenzo, Samuele Cortese, Nicoletta Adamo, Luigi Janiri
Attention-deficit/hyperactivity disorder (ADHD) is characterised by a persistent and impairing pattern of inattention and/or hyperactivity/impulsivity and it is one of the most common neuropsychiatric conditions. Evidence about interventions of adults with ADHD is growing rapidly and clinicians need a reliable summary of all the best available information in order to better inform their daily practice. We searched MEDLINE, PubMed, PsycINFO and Cochrane databases until 31 May 2016 for systematic reviews about pharmacological and non-pharmacological treatments in adults with ADHD and carried out a meta-review to address clinically relevant questions...
February 2017: Evidence-based Mental Health
https://www.readbyqxmd.com/read/27991835/parent-reported-improvements-in-family-functioning-in-a-randomized-controlled-trial-of-lisdexamfetamine-for-treatment-of-parental-attention-deficit-hyperactivity-disorder
#20
Dara E Babinski, James G Waxmonsky, Daniel A Waschbusch, Hugh Humphery, William E Pelham
OBJECTIVE: This study examines the effects of parental stimulant medication treatment on parent ratings of parent-child functioning. Ratings of parent-child functioning in the home setting and immediately following a laboratory-based parent-child interaction were collected. METHOD: Participants were 20 parents who along with their children (ages 5-12 years) were diagnosed with Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) attention-deficit/hyperactivity disorder (ADHD)...
April 2017: Journal of Child and Adolescent Psychopharmacology
keyword
keyword
7577
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"